‘16% of cancer patients on CAM therapies have taken fenbendazole’ (2022)

News Report · Song Soo-youn (Korea Biomedical Review) · June 13, 2022

Song Soo-youn (Korea Biomedical Review), 2022-06-13: Korean trade-press report of a survey presented at a cancer forum: of 221 patients in nine cancer patient groups, 173 used complementary medicine and 16.2% of those (28 patients) had taken fenbendazole, with younger and metastatic patients more likely to have done so.

About 78 percent, or 173 patients, said that they used CAM. Of 173, 16.2 percent or 28 patients said they had taken fenbendazole.

Article body (unpaginated)

Song Soo-youn (Korea Biomedical Review), 2022-06-13: Korean trade-press report of a survey presented at a cancer forum: of 221 patients in nine cancer patient groups, 173 used complementary medicine and 16.2% of those (28 patients) had taken fenbendazole, with younger and metastatic patients more likely to have done so. Study type: news report of a conference presentation by Prof. Kim Jung-sun and Prof. Kwon Jung-hye, Chungnam National University Sejong Hospital; the underlying survey is of 221 members of nine Korean cancer patient groups (renal cancer, multiple myeloma and others), n=173 CAM users, 28 fenbendazole users. A second survey cited in the same article covered 1,804 patients at 19 institutions, of whom 58% of CAM users did not tell their doctor. Country: South Korea. Dose, schedule, funder and conflicts of interest of the survey are not reported in the news item. Comparator: none. Quoted statement attributed to Prof. Kwon: many papers patients cite 'are fake, some are only in the stage of cells, and some others showed that fenbendazole worsened cancer.' Study type: news.